Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

MobiliTraIN Ion Mobility Mass Spectrometry Training Network

Coordinator
Universitaet Fuer Bodenkultur Wien, Austria
Runs
1 February 2024 to 31 January 2028
Status
Running
EU funding
€2.7m
Total cost
—
Partners
23 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119562

What the project is doing

In the project's own words, from its summary on CORDIS.

Ion mobility-high resolution mass spectrometry (IM-HRMS) is the next-generation analytical platform in research and industry. Unlocking its full potential across applications as varied as biotherapeutics, environment and food safety requires not only pushing back the frontiers of instrumentation, fundamental understanding and applications – but harmonisation is essential. To achieve this, current shortcomings in data collection, analysis and reporting across instrument types, laboratories and research areas need to be scrutinised and overcome.

The MobiliTraIN Doctoral Network will form 13 Doctoral Candidates (DCs) who will bring a new fundamental understanding of IM-HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for the application of IM-HRMS in biopharmaceutical development, biological ‘omics studies, and nontarget screening of contaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary research programme, including an open science approach and training in technical, business and transferable skills, the MobiliTraIN DCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers while supporting Europe’s innovation capacity.

Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS development and application, MobiliTraIN unites 10 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1 pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoring experience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics, better understanding of complex disease progression and improved monitoring of food, water and public health safety.

Topics

Who is involved

OrganisationCityCountryRole
Universitaet Fuer Bodenkultur WienWienAustriaCoordinator
Janssen Pharmaceutica NVBeerseBelgiumAssociatedpartner
Quality AssistanceDonstiennesBelgiumAssociatedpartner
Universiteit AntwerpenAntwerpenBelgiumParticipant
Accelopment Schweiz AGZurichSwitzerlandAssociatedpartner
Universite De GeneveGeneveSwitzerlandAssociatedpartner
envibee GmbHDübendorfSwitzerlandAssociatedpartner
Analytisches Forschungsinstitut für Non-Target Screening GmbH (AFIN-TS)WallersteinGermanyAssociatedpartner
Bruker Daltonics GmbH & Co KgBremenGermanyParticipant
Bundesanstalt Fuer Materialforschung Und -PruefungBerlinGermanyAssociatedpartner
Freie Universitaet BerlinBerlinGermanyParticipant
Gilles ToussaintGermanyAssociatedpartner
Universitatsklinikum JenaJenaGermanyParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Ecole Nationale Veterinaire, Agroalimentaire Et De L'alimentation Nantes AtlantiqueNantesFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite De BordeauxBordeauxFranceAssociatedpartner
Universite De MontpellierMontpellierFranceAssociatedpartner
Universite De StrasbourgStrasbourgFranceAssociatedpartner
Uppsala UniversitetUppsalaSwedenParticipant
Micromass UK LtdWilmslow CheshireUnited KingdomAssociatedpartner
The University of ManchesterManchesterUnited KingdomAssociatedpartner
Agilent Technologies, Inc.Santa ClaraUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI